Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...

After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 ...

MONTANA - Diabetes is a widespread issue throughout the United States, and Montana is no exception. According to the American ...

Under the theme of this year s World Diabetes Day, Diabetes and well being and with the participation of a distinguished ...

One man’s story of recovery from diabetes, and how the community can help on the way, has been added to a health awareness ...

We are living in exciting times regarding therapies for people with diabetes. Much of the excitement ... precise regulatory guidance will still be needed for discussion and decision making about ...

Good morning, ladies and gentlemen, and welcome to the Humacyte Third Quarter 2024 Results Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and ...

During a routine wellness check, the doctor’s words struck a chord with Maria Parsell: her blood sugar had climbed to a pre-diabetic range.

Taking steps to prevent and manage diabetes by blood sugar monitoring ... rapidly and can enter advanced stages with little warning. Engaging patients in discussions about risk factors and symptoms ...

Lexicon Pharmaceuticals received a negative vote from a Food and Drug Administration advisory committee for Zynquista as an adjunct to insulin therapy for glycemic control in adults with Type 1 ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...